Trial Profile
The efficacy and saftey of Avastin plus S-1 compared with Docetaxel in the second line treatment of advanced lung adenocarcinoma with negtive driven gene
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2018 New trial record